Tarveda Therapeutics Garners $38,000,000 Series C Funding Round

  • Feed Type
  • Date
    1/27/2016
  • Company Name
    Tarveda Therapeutics
  • Mailing Address
    134 Coolidge Avenue Watertown, MA 02472 USA
  • Company Description
    Tarveda creates Pentarins that are targeted miniature drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger antibody drug conjugates in use and development today.
  • Website
    http://www.tarveda.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the Series C financing will be used to advance a pipeline of Pentarins that Tarveda is developing for a range of solid tumor targets. In particular, the funding will support the advancement of Tarveda’s lead drug candidate, PEN-221, into Phase 1 clinical studies in mid-2016. PEN-221 is designed to target the somatostatin receptor for treatment of patients with neuroendocrine cancers including small cell lung cancer.
  • M&A Terms
  • Venture Investor
    Novo Ventures
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Flagship Ventures
  • Venture Investor
    NanoDimension
  • Venture Investor
    Eminent Venture Capital

Trending on Xconomy